# A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

> **NCT02655016** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Tesaro, Inc.** · enrollment: 733 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02655016
- **Lead sponsor:** Tesaro, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-11
- **Primary completion:** 2019-05-17
- **Final completion:** 2026-05-29
- **Target enrollment:** 733 (ACTUAL)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02655016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02655016, "A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02655016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*